Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Apr 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-04-01

Reporting Person: Young David (Director, Chief Executive Officer, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-01	Restricted Stock Units	$0	A	247841	Acquired		Common Stock (247841)	Direct

Footnotes

F1: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.

F2: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person.